Policy Endorsement and Booster Shot: Exploring Politicized Determinants for Acceptance of a Third Dose of COVID-19 Vaccine in China

Author:

Zhang Ruifen1,Yan Jun2,Jia Hepeng13ORCID,Luo Xi1,Liu Qinliang1ORCID,Lin Jingke4

Affiliation:

1. School of Communication, Soochow University, Suzhou 215127, China

2. School of Journalism and Information Communication, Huazhong University of Science and Technology, Wuhan 430074, China

3. School of Public Health, Soochow University, Suzhou 215127, China

4. School of Journalism and Communication, Sun Yat-sen University, Guangzhou 510006, China

Abstract

China’s recent termination of strict COVID-19 control necessitates taking a booster vaccine shot as a precaution against the pandemic as quickly as possible. A large body of research has examined people’s attitudes toward and intentions for the booster shot. However, most studies failed to explore how China’s sociopolitical context has shaped their attitude regarding the booster jab take-up. The current study utilizes data from a national survey adopting quota sampling to analyze the Chinese public’s medical and non-medical considerations to determine their intention for the third dose of the COVID-19 vaccine. The study found that thanks to China’s initial successful lockdown policies, personal risk and benefit perceptions did not dominate their views regarding booster vaccination. Instead, respondents’ gender, nationalism, endorsement of the zero-COVID policy, self-efficacy regarding vaccination, and perceived infection severity were the major factors underlying their booster shot intention. The situation highlights how the politicized context of China’s COVID-19 control has impacted people’s plans to practice preventive behaviors. It is necessary to offset the negative consequences. One strategy is to educate the Chinese public with more medically relevant information to help them make rational choices regarding vaccination and other protective measures. On the other hand, such education can utilize this nationalistic mental status to enhance the persuasion effect.

Funder

National Social Science Foundation of China

Postgraduate Research & Practice Innovation Program of Jiangsu Province

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference49 articles.

1. Chien, A.C., Che, C., and Liu, J. (2022, December 28). ‘Zero Covid,’ Once Ubiquitous, Vanishes in China’s Messy Pivot. The New York Times 9 December 2022. Available online: https://www.nytimes.com/2022/2012/2008/world/asia/china-covid-rollback.html.

2. Chan, E., and Zheng, S. (2022, December 28). ‘It Doesn’t Hurt at All’: In China’s New Covid Strategy, Vaccines Matter. The New York Times 12 December 2022. Available online: https://www.nytimes.com/2022/2012/2012/business/china-covid-zero-vaccines.html.

3. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England;Andrews;Nat. Med.,2022

4. Are COVID-19 vaccine boosters needed? The science behind boosters;Burckhardt;J. Virol.,2022

5. Hu, D., Liu, Z., Gong, L., Kong, Y., Liu, H., Wei, C., Wu, X., Zhu, Q., and Guo, Y. (2022). Exploring the Willingness of the COVID-19 Vaccine Booster Shots in China Using the Health Belief Model: Web-Based Online Cross-Sectional Study. Vaccines, 10.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3